Respuesta inmune humoral a cuatro vacunas contra el SARS-CoV-2 en profesionales de la salud

Arturo Pareja Cruz, Julio César Luque Espino, Pedro Javier Navarrete Mejía, Joel de León Delgado, Jesús Demóstenes Gonzáles Moscoso
{"title":"Respuesta inmune humoral a cuatro vacunas contra el SARS-CoV-2 en profesionales de la salud","authors":"Arturo Pareja Cruz, Julio César Luque Espino, Pedro Javier Navarrete Mejía, Joel de León Delgado, Jesús Demóstenes Gonzáles Moscoso","doi":"10.24265/horizmed.2022.v22n2.06","DOIUrl":null,"url":null,"abstract":"Objective: To describe the concentration of neutralizing antibodies in serum from healthcare professionals who received any of the SARS-CoV-2 vaccines developed by Sinopharm, Pfizer or Johnson & Johnson, or CureVac’s vaccine candidate. Materials and methods: An observational, descriptive, retrospective, cross-sectional research which included 217 healthcare professionals fully vaccinated with Sinopharm, Pfizer or Johnson & Johnson’s vaccines, or CureVac’s vaccine candidate. The presence of anti-SARS-CoV-2 neutralizing antibodies in serum was determined in these individuals using the electrochemiluminescence immunoassay (ECLIA). Variables such as age, sex, history of infection with SARS-CoV-2, concentration of neutralizing antibodies and brand of vaccine administered were considered. Results: Sixteen point six zero percent (16.60 %) of the healthcare professionals stated that they had already had COVID-19 before receiving the vaccine. They were immunized with the vaccines developed by Sinopharm (74.65 %), Pfizer (12.90 %) or Johnson & Johnson (5.07 %), or CureVac’s vaccine candidate (7.37 %). Regardless of the vaccine received, 42.50 % of the individuals who had not been previously infected with SARS-CoV-2 and 16.70 % of those who had been previously infected Arturo Pareja Cruz; Julio César Luque Espino; Pedro Javier Navarrete Mejía; Joel de León Delgado; Jesús Demóstenes Gonzáles Moscoso https://doi.org/10.24265/horizmed.2022.v22n2.06 did not develop neutralizing antibodies. Pfizer’s vaccine produced the highest concentration of neutralizing antibodies (196.27 AU/mL) in patients with or without previous infection. Conclusions: The study demonstrates that vaccination boosts immunity in people previously infected with the novel coronavirus and suggests that Pfizer’s vaccine produces the highest concentration of neutralizing antibodies.","PeriodicalId":396953,"journal":{"name":"Horizonte Médico (Lima)","volume":"4 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Horizonte Médico (Lima)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24265/horizmed.2022.v22n2.06","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To describe the concentration of neutralizing antibodies in serum from healthcare professionals who received any of the SARS-CoV-2 vaccines developed by Sinopharm, Pfizer or Johnson & Johnson, or CureVac’s vaccine candidate. Materials and methods: An observational, descriptive, retrospective, cross-sectional research which included 217 healthcare professionals fully vaccinated with Sinopharm, Pfizer or Johnson & Johnson’s vaccines, or CureVac’s vaccine candidate. The presence of anti-SARS-CoV-2 neutralizing antibodies in serum was determined in these individuals using the electrochemiluminescence immunoassay (ECLIA). Variables such as age, sex, history of infection with SARS-CoV-2, concentration of neutralizing antibodies and brand of vaccine administered were considered. Results: Sixteen point six zero percent (16.60 %) of the healthcare professionals stated that they had already had COVID-19 before receiving the vaccine. They were immunized with the vaccines developed by Sinopharm (74.65 %), Pfizer (12.90 %) or Johnson & Johnson (5.07 %), or CureVac’s vaccine candidate (7.37 %). Regardless of the vaccine received, 42.50 % of the individuals who had not been previously infected with SARS-CoV-2 and 16.70 % of those who had been previously infected Arturo Pareja Cruz; Julio César Luque Espino; Pedro Javier Navarrete Mejía; Joel de León Delgado; Jesús Demóstenes Gonzáles Moscoso https://doi.org/10.24265/horizmed.2022.v22n2.06 did not develop neutralizing antibodies. Pfizer’s vaccine produced the highest concentration of neutralizing antibodies (196.27 AU/mL) in patients with or without previous infection. Conclusions: The study demonstrates that vaccination boosts immunity in people previously infected with the novel coronavirus and suggests that Pfizer’s vaccine produces the highest concentration of neutralizing antibodies.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
卫生专业人员对四种SARS-CoV-2疫苗的体液免疫反应
目的:描述接受国药、辉瑞或强生研发的SARS-CoV-2疫苗或CureVac候选疫苗的医护人员血清中中和抗体的浓度。材料和方法:一项观察性、描述性、回顾性、横断面研究,包括217名完全接种国药、辉瑞或强生疫苗或CureVac候选疫苗的医疗保健专业人员。使用电化学发光免疫分析法(ECLIA)确定这些个体血清中是否存在抗sars - cov -2中和抗体。考虑了年龄、性别、SARS-CoV-2感染史、中和抗体浓度和接种疫苗品牌等变量。结果:16.6%(16.60%)的医护人员表示他们在接种疫苗前已经感染了COVID-19。分别接种国药(74.65%)、辉瑞(12.90%)、强生(5.07%)和CureVac候选疫苗(7.37%)。无论接种何种疫苗,以前未感染过SARS-CoV-2的个体中有42.50%和以前感染过SARS-CoV-2的个体中有16.70%;胡里奥·凯萨·卢克·埃斯皮诺;Pedro Javier Navarrete Mejía;乔尔·德León德尔加多;Jesús Demóstenes Gonzáles莫斯科索https://doi.org/10.24265/horizmed.2022.v22n2.06没有产生中和抗体。辉瑞公司的疫苗在既往感染或未感染的患者中产生最高浓度的中和抗体(196.27 AU/mL)。结论:该研究表明,接种疫苗可以增强以前感染过新型冠状病毒的人的免疫力,并表明辉瑞公司的疫苗产生的中和抗体浓度最高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
El profesionalismo y la educación médica Programa de intervención farmacéutica periférica para la prevención de anemia ferropénica en niños Hemoglobina como predictor del recuento de hematocrito y hematíes según edad y sexo en una población de Villa El Salvador en Lima-Perú Factores asociados al miedo a la COVID-19 previo al retorno a clases presenciales en una facultad de Medicina peruana Hernia hiatal gigante: presentación de un caso clínico
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1